Evaluation of OK-432 Injection Therapy as Possible Primary Treatment of Intraoral Ranula
Evaluation of OK-432 Injection Therapy as Possible Primary Treatment of Intraoral Ranula
复制标题
DOI：
10.1016/j.joms.2016.08.013
复制
发表时间：
2017-02-01
影响因子：
1.9
通讯作者：
Chikazu, Daichi
中科院分区：
文献类型：
--
作者：
Kono, Michihide;Satomi, Takafumi;Chikazu, Daichi
目的：舌核是由舌下腺粘液渗出引起的假性囊肿。最近，一种硬化剂OK-432(Picibanil)被报道对治疗淋巴管瘤和宫颈囊性病变非常有效。本研究对OK-432注射治疗口腔内颗粒的疗效进行评估，以明确其是否可以作为主要治疗方法。患者和方法：本研究是2005-2015年间接受OK-432注射治疗的口腔内颗粒的临床回顾研究。在计算机断层扫描或磁共振成像研究中测量颗粒大小。我们将1Klinische Einheit(KE)单位的OK-432粉末溶解在等于抽吸量的生理盐水中。主要终点是治疗结果。次要终点是指治疗结果与病变长度和抽吸量的关系。结果：23例患者接受了OK-432口腔内颗粒注射治疗。病变平均大小为19.96 mm。平均抽吸量为2.14毫升。注射次数1~4次，平均1.70次。末次注射后完全消退(CR)18例(78.2%)，部分消退(PR)3例(13.0%)，无效(NR)2例(8%)。总有效率为91.2%(21/23)。无严重并发症发生。CR组病灶长度为17.38 mm，抽吸量为1.40mL。PR/NR组病灶长度为29.20 mm，抽吸量为4.80mL。PR/NR组的病变面积明显大于CR组。结论：OK-432注射治疗口腔黏膜瘤较其他手术方法安全、有效。这种疗法有可能成为口腔内肉芽肿的主要治疗方法。(C)2016年美国口腔颌面外科医生协会
Purpose: A ranula is a pseudocyst caused by mucous extravasation from the sublingual gland. Recently, a sclerosing agent, OK-432 (picibanil), has been reported to be highly effective for treating lymphangioma and cervical cystic lesions. The present study assessed the effectiveness of OK-432 injection therapy for intraoral ranula to clarify whether it can be used as the primary treatment.Patients and Methods: The present study was a retrospective clinical study of patients with intraoral ranula who received OK-432 injection therapy from 2005 to 2015. The ranula size was measured on computed tomography or magnetic resonance imaging studies. We dissolved 1 Klinische Einheit (KE) unit of OK-432 powder in normal saline equal to the aspiration volume. The primary endpoint was the treatment results. The secondary endpoints were the relation between the treatment results and the lesion length and aspiration volume.Results: A total of 23 patients received OK-432 injection therapy for an intraoral ranula. The mean lesion size was 19.96 mm. The mean aspiration volume was 2.14 mL. The number of injections was 1 to 4 (mean 1.70). The treatment results were complete regression (CR) in 18 (78.2%), partial regression (PR) in 3 (13.0%), and no response (NR) in 2 (8%) patients after the last injection. The overall efficacy rate was 91.2% (21 of 23). No serious complications were observed. The lesion length and aspiration volume of the CR group was 17.38 mm and 1.40 mL, respectively. The lesion length and aspiration volume of the PR/NR group was 29.20 mm and 4.80 mL, respectively. The PR/NR group lesions were significantly larger than the CR group lesions.Conclusions: OK-432 injection therapy for intraoral ranula is safe and effective compared with other surgical therapies. This therapy could potentially become a primary treatment of intraoral ranula. (C) 2016 American Association of Oral and Maxillofacial Surgeons